COVID-19 Induced Cardiovascular Complications and Recent Therapeutic Advances


  •   Selia Chowdhury

  •   Mehedi Hasan Bappy

  •   Samia Chowdhury

  •   Md. Shahraj Chowdhury

  •   Nurjahan Shipa Chowdhury


A global pandemic instigated by SARS-CoV-2 virus has been going strongly for almost two years. There have been almost 240 million cases with almost 5 million fatalities all over the world so far. COVID has affected almost every aspect of people’s lives halting the world in immeasurable ways. Although COVID-19 is mostly affecting the respiratory system, it is also responsible for a significant amount of cardiovascular system involvement. On one hand, it deteriorates any pre-existing cardiovascular condition, on another hand, it triggers other inflammation-facilitated acute events. They comprise of inflammatory heart disease, severe pericardial effusion, ventricular arrhythmias, endothelial dysfunction, pulmonary hypertension, heart failure, and many more. In this article, we summarize the features, management, and treatment of several important COVID-19 induced cardiovascular complications. Recent advances in the treatment of these diseases along with the justification and concerns of specific therapeutic measures are also discussed.

Keywords: Cardiovascular, management, therapeutics, COVID-19


“COVID live update: 245,121,473 cases and 4,975,150 deaths from the Coronavirus - worldometer,” [Online]. Available: [Accessed: 26-Oct-2021].

E. A. Adeghate, N. Eid, and J. Singh, “Mechanisms of COVID-19-induced heart failure: a short review,” Heart Fail. Rev., vol. 26, no. 2, pp. 363–369, 2021. DOI:

F. Mai, R. Del Pinto, and C. Ferri, “COVID-19 and cardiovascular diseases,” J. Cardiol., vol. 76, no. 5, pp. 453–458, 2020. DOI:

V. Gerc, I. Masic, N. Salihefendic, and M. Zildzic, “Cardiovascular diseases (CVDs) in COVID-19 pandemic era,” Mater. Sociomed., vol. 32, no. 2, pp. 158–164, 2020. DOI:

M. Boukhris et al., “Cardiovascular implications of the COVID-19 pandemic: A global perspective,” Can. J. Cardiol., vol. 36, no. 7, pp. 1068–1080, 2020. DOI:

D. Atri, H. K. Siddiqi, J. P. Lang, V. Nauffal, D. A. Morrow, and E. A. Bohula, “COVID-19 for the cardiologist: Basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies,” JACC Basic Transl. Sci., vol. 5, no. 5, pp. 518–536, 2020. DOI:

J. M. Pericàs et al., “COVID-19: from epidemiology to treatment,” Eur. Heart J., vol. 41, no. 22, pp. 2092–2112, 2020.

T. Guo et al., “Cardiovascular implications of fatal outcomes of patients with Coronavirus disease 2019 (COVID-19),” JAMA Cardiol., vol. 5, no. 7, pp. 811–818, 2020. DOI:

O. K. Abou Hassan, C. C. Sheng, T. K. M. Wang, and P. C. Cremer, “SARS-CoV-2 myocarditis: Insights into incidence, prognosis, and therapeutic implications,” Curr. Cardiol. Rep., vol. 23, no. 9, p. 129, 2021. DOI:

CDC COVID-19 Response Team, “Severe outcomes among patients with Coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020,” MMWR Morb. Mortal. Wkly. Rep., vol. 69, no. 12, pp. 343–346, 2020. DOI:

T. S. M. Tsang et al., “Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: Clinical profile, practice patterns, and outcomes spanning 21 years,” Mayo Clin. Proc., vol. 77, no. 5, pp. 429–436, 2002. DOI:

M. Kermani-Alghoraishi, A. Pouramini, F. Kafi, and A. Khosravi, “Coronavirus disease 2019 (COVID-19) and severe pericardial effusion: From pathogenesis to management: A case report based systematic review,” Curr. Probl. Cardiol., no. 100933, p. 100933, 2021. DOI:

A. Rivero, A. Aceña, M. Orejas, and R. Hernandez-Estefania, “Recurrent haemorrhagic pericardial effusion due to idiopathic pericarditis: a case report,” Eur. Heart J. Case Rep., vol. 3, no. 1, p. ytz018, 2019. DOI:

F. Sauer, C. Dagrenat, P. Couppie, G. Jochum, and P. Leddet, “Pericardial effusion in patients with COVID-19: case series,” Eur. Heart J. Case Rep., vol. 4, no. FI1, pp. 1–7, 2020. DOI:

K. E. Parsova, L. Pay, Y. Oflu, R. Hacıyev, and G. Çinier, “A rare presentation of a patient with COVID-19: Cardiac tamponade,” Turk Kardiyol. Dern. Ars., vol. 48, no. 7, pp. 703–706, 2020. DOI:

M. F. Dabbagh, L. Aurora, P. D’Souza, A. J. Weinmann, P. Bhargava, and M. B. Basir, “Cardiac tamponade secondary to COVID-19,” JACC Case Rep, vol. 2, no. 9, pp. 1326–1330, 2020. DOI:

C. Ejikeme, M. Gonzalez, S. Elkattawy, R. Alyacoub, and C. Sherer, “Subacute COVID-19 infection presenting as indolent large pericardial effusion,” Cureus, vol. 12, no. 10, p. e10769, 2020. DOI:

A. Reddy, S. Nethercott, R. Duehmke, S. Nair, and O. Abdul-Samad, “‘dry’ pericarditis with rapid progression to tamponade as a feature of COVID-19,” European Medical Journal, 2021. DOI:

M. Imazio et al., “Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality: Safety and potentiality,” J. Cardiovasc. Med. (Hagerstown), vol. 21, no. 9, pp. 625–629, 2020. DOI:

F. Kafi, A. Bolourian, Z. Mojtahedi, and A. Pouramini, “High mobility group box 1 (HMGB1) in COVID-19,” J. Prev. Epidemiol., vol. 6, no. 1, pp. e11–e11, 2021. DOI:

H. Karmouty-Quintana, R. A. Thandavarayan, S. P. Keller, S. Sahay, L. M. Pandit, and B. Akkanti, “Emerging mechanisms of pulmonary vasoconstriction in SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) and potential therapeutic targets,” Int. J. Mol. Sci., vol. 21, no. 21, p. 8081, 2020. DOI:

S. Kache et al., “COVID-19 PICU guidelines: for high- and limited-resource settings,” Pediatr. Res., vol. 88, no. 5, pp. 705–716, 2020. DOI:

“ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic,” [Online]. Available: [Accessed: 26-Oct-2021].

H. M. Al-Kuraishy, A. I. Al-Gareeb, M. S. Al-Niemi, A. K. Al-Buhadily, N. A. Al-Harchan, and C. Lugnier, “COVID-19 and phosphodiesterase enzyme type 5 inhibitors,” J. Microsc. Ultrastruct., vol. 8, no. 4, pp. 141–145, 2020. DOI:

W.-X. Feng, Y. Yang, J. Wen, Y.-X. Liu, L. Liu, and C. Feng, “Implication of inhaled nitric oxide for the treatment of critically ill COVID-19 patients with pulmonary hypertension,” ESC Heart Fail., vol. 8, no. 1, pp. 714–718, 2021. DOI:

B. Yu, M. J. Raher, G. P. Volpato, K. D. Bloch, F. Ichinose, and W. M. Zapol, “Inhaled nitric oxide enables artificial blood transfusion without hypertension,” Circulation, vol. 117, no. 15, pp. 1982–1990, 2008. DOI:

M. P. Nägele, B. Haubner, F. C. Tanner, F. Ruschitzka, and A. J. Flammer, “Endothelial dysfunction in COVID-19: Current findings and therapeutic implications,” Atherosclerosis, vol. 314, pp. 58–62, 2020. DOI:

D. Wang et al., “Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China,” JAMA, vol. 323, no. 11, pp. 1061–1069, 2020. DOI:

A. R. Akkawi and M. Ghazal, “COVID-19 and cardiac arrhythmias: A review of the literature,” Cureus, 2021. DOI:

T.-Y. Xiong, S. Redwood, B. Prendergast, and M. Chen, “Coronaviruses and the cardiovascular system: acute and long-term implications,” Eur. Heart J., vol. 41, no. 19, pp. 1798–1800, 2020. DOI:

M. Traebert, B. Dumotier, L. Meister, P. Hoffmann, M. Dominguez-Estevez, and W. Suter, “Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells,” Eur. J. Pharmacol., vol. 484, no. 1, pp. 41–48, 2004. DOI:

J. Demazière, J. M. Fourcade, C. T. Busseuil, P. Adeleine, S. M. Meyer, and J. M. Saïssy, “The hazards of chloroquine self prescription in west Africa,” J. Toxicol. Clin. Toxicol., vol. 33, no. 4, pp. 369–370, 1995. DOI:

A. Cervera, G. Espinosa, J. Font, and M. Ingelmo, “Cardiac toxicity secondary to long term treatment with chloroquine,” Ann. Rheum. Dis., vol. 60, no. 3, p. 301, 2001. DOI:

J. Carron, Z. Sharif, H. Hussein, M. Kennedy, B. McAdam, and R. Sheahan, “Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic,” Ir. J. Med. Sci., vol. 190, no. 1, pp. 403–409, 2021. DOI:

H. Onohuean, H. M. Al-Kuraishy, A. I. Al-Gareeb, S. Qusti, E. M. Alshammari, and G. E.-S. Batiha, “Covid-19 and development of heart failure: mystery and truth,” Naunyn. Schmiedebergs. Arch. Pharmacol., vol. 394, no. 10, pp. 2013–2021, 2021. DOI:

F. Zhou et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” Lancet, vol. 395, no. 10229, pp. 1054–1062, 2020. DOI:

X. Peng et al., “Promising therapy for heart failure in patients with severe COVID-19: Calming the cytokine storm,” Cardiovasc. Drugs Ther., vol. 35, no. 2, pp. 231–247, 2021. DOI:

C. Burkard et al., “ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells,” J. Virol., vol. 89, no. 8, pp. 4434–4448, 2015. DOI:

K. Ihenetu, R. Espinosa, R. de Leon, G. Planas, A. Perez-Pinero, and L. Waldbeser, “Digoxin and digoxin-like immunoreactive factors (DLIF) modulate the release of pro-inflammatory cytokines,” Inflamm. Res., vol. 57, no. 11, pp. 519–523, 2008. DOI:

J. Lee et al., “Digoxin ameliorates autoimmune arthritis via suppression of Th17 differentiation,” Int. Immunopharmacol., vol. 26, no. 1, pp. 103–111, 2015. DOI:

C. Skayem and N. Ayoub, “Carvedilol and COVID-19: A potential role in reducing infectivity and infection severity of SARS-CoV-2,” Am. J. Med. Sci., vol. 360, no. 3, p. 300, 2020. DOI:

T. Kurum, E. Tatli, and M. Yuksel, “Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy,” Tex. Heart Inst. J., vol. 34, no. 1, pp. 52–59, 2007.

K. Kotfis et al., “COVID-19-the potential beneficial therapeutic effects of spironolactone during SARS-CoV-2 infection,” Pharmaceuticals (Basel), vol. 14, no. 1, p. 71, 2021. DOI:

B. Bozkurt, I. Kamat, and P. J. Hotez, “Myocarditis with COVID-19 mRNA vaccines,” Circulation, vol. 144, no. 6, pp. 471–484, 2021. DOI:

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, “The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2,” Nat. Microbiol., vol. 5, no. 4, pp. 536–544, 2020. DOI:

M. Marshall et al., “Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination,” Pediatrics, vol. 148, no. 3, p. e2021052478, 2021. DOI:

B. J. Maron et al., “Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task force 3: Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: A scientific statement from the American heart association and American college of cardiology,” J. Am. Coll. Cardiol., vol. 66, no. 21, pp. 2362–2371, 2015. DOI:

D. B. Cines and J. B. Bussel, “SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia,” N. Engl. J. Med., vol. 384, no. 23, pp. 2254–2256, 2021. DOI:

A. Greinacher, T. Thiele, T. E. Warkentin, K. Weisser, P. A. Kyrle, and S. Eichinger, “Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination,” N. Engl. J. Med., vol. 384, no. 22, pp. 2092–2101, 2021. DOI:

K.-L. Muir, A. Kallam, S. A. Koepsell, and K. Gundabolu, “Thrombotic thrombocytopenia after Ad26.COV2.S vaccination,” N. Engl. J. Med., vol. 384, no. 20, pp. 1964–1965, 2021. DOI:

I. See et al., “US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021,” JAMA, vol. 325, no. 24, pp. 2448–2456, 2021. DOI:

K. L. Furie, M. Cushman, M. S. V. Elkind, P. D. Lyden, G. Saposnik, and American Heart Association/American Stroke Association Stroke Council Leadership, “Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia,” Stroke, vol. 52, no. 7, pp. 2478–2482, 2021. DOI:

L. Italia et al., “COVID-19 and heart failure: From epidemiology during the pandemic to myocardial injury, myocarditis, and heart failure sequelae,” Front. Cardiovasc. Med., vol. 8, p. 713560, 2021. DOI:

C. Huang et al., “6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,” Lancet, vol. 397, no. 10270, pp. 220–232, 2021. DOI:

B. van den Borst et al., “Comprehensive health assessment 3 months after recovery from acute Coronavirus disease 2019 (COVID-19),” Clin. Infect. Dis., vol. 73, no. 5, pp. e1089–e1098, 2021. DOI:

V. O. Puntmann et al., “Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus disease 2019 (COVID-19),” JAMA Cardiol., vol. 5, no. 11, pp. 1265–1273, 2020. DOI:

C. J. Daniels et al., “Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: Results from the big Ten COVID-19 Cardiac Registry: Results from the big ten COVID-19 cardiac registry,” JAMA Cardiol., vol. 6, no. 9, pp. 1078–1087, 2021.

D. Brito et al., “High prevalence of pericardial involvement in college student athletes recovering from COVID-19,” JACC Cardiovasc. Imaging, vol. 14, no. 3, pp. 541–555, 2021. DOI:

L. T. Weckbach et al., “Myocardial inflammation and dysfunction in COVID-19-associated myocardial injury,” Circ. Cardiovasc. Imaging, vol. 14, no. 1, p. e012220, 2021. DOI:

G. Zaccone, D. Tomasoni, L. Italia, C. M. Lombardi, and M. Metra, “Myocardial involvement in COVID-19: An interaction between comorbidities and heart failure with preserved ejection fraction. A further indication of the role of inflammation,” Curr. Heart Fail. Rep., vol. 18, no. 3, pp. 99–106, 2021. DOI:

Most read articles by the same author(s)